文献速递头颈与中枢神经肿瘤

TeloDIAG:端粒参数如何助力胶质瘤快速诊断与液体活检

The TeloDIAG: how telomeric parameters can help in glioma rapid diagnosis and liquid biopsy approaches.
PubMed 文献 · Ann Oncol · 2021-10-22

该研究将C-circle(CC)检测适配于肿瘤和血液样本,构建了基于CC的端粒维持机制(TMM)识别算法,并联合IDH突变状态与组织学分级提出TeloDIAG分类工具。TeloDIAG与WHO分类一致性达99%,并可修正部分非典型分子特征胶质瘤的分类,血液CC检测在IDH突变型星形细胞瘤中展现液体活检潜力。

要点

  • TeloDIAG分类工具基于CC检测的TMM、IDH突变状态和组织学分级,与WHO分类一致性99%。
  • CC检测识别TMM的灵敏度100%、特异度97.3%(n=284例胶质瘤)。
  • 血液CC检测在IDH突变型星形细胞瘤患者中灵敏度56%、特异度97%(n=206例胶质瘤和30例健康供者)。

核心结论

  • TeloDIAG是一种简单有效的胶质瘤诊断工具,并有潜力用于液体活检。

研究设计与样本

  • 研究将C-circle(CC)检测适配于肿瘤(福尔马林固定石蜡包埋和冷冻)和血液样本,以探究端粒维持机制(TMM)。

主要发现

  • 基于CC的算法识别TMM的灵敏度为100%,特异度为97.3%(n=284例胶质瘤)。
  • TeloDIAG定义五种亚型:tOD、tLGA、tGBM_IDHmt、tGBM和tAIV,分别对应少突胶质细胞瘤、IDH突变型低级别星形细胞瘤、IDH突变型胶质母细胞瘤、IDH野生型胶质母细胞瘤(GBM),以及ALT+ IDH野生型胶质瘤(tAIV)。
  • tAIV倾向于比tGBM有更长生存期(21.2个月 vs 16.5个月)。
  • TeloDIAG与WHO分类一致性为99%(n=312),并进一步修正了55/144(38%)具有非典型分子特征胶质瘤的分类。
  • 在69例TERTwt、ATRXwt、IDHwt GBM中,有14例(20%)实际为tAIV。

临床怎么用

  • TeloDIAG可辅助胶质瘤诊断,尤其有助于识别非典型分子特征病例的亚型分类。
  • 血液CC检测可作为IDH突变型星形细胞瘤液体活检的潜在选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In glioma, TERT promoter mutation and loss of ATRX (ATRX loss) are associated with reactivation of telomerase or alternative lengthening of telomeres (ALT), respectively, i.e. the two telomere maintenance mechanisms (TMM). Strangely, 25% of gliomas have been reported to display neither or both of these alterations. MATERIALS AND METHODS: The C-circle (CC) assay was adapted to tumor (formalin-fixed paraffin-embedded and frozen) and blood samples to investigate the TMM. RESULTS: We constructed a CC-based algorithm able to identify the TMM and reported a sensitivity of 100% and a specificity of 97.3% (n = 284 gliomas). By combining the TMM, the mutational status of the isocitrate dehydrogenase 1/2 (IDH) gene (IDHmt), and the histological grading, we propose a new classification tool: TeloDIAG. This classification defined five subtypes: tOD, tLGA, tGBM_IDHmt, tGBM, and tAIV, corresponding to oligodendroglioma, IDHmt low-grade astrocytoma, IDHmt glioblastoma, and IDHwt glioblastoma (GBM), respectively; the last class gathers ALT+ IDHwt gliomas that tend to be related to longer survival (21.2 months) than tGBM (16.5 months). The TeloDIAG was 99% concordant with the World Health Organization classification (n = 312), and further modified the classification of 55 of 144 (38%) gliomas with atypical molecular characteristics. As an example, 14 of 69 (20%) of TERTwt, ATRXwt, and IDHwt GBM were actually tAIV. Outstandingly, CC in blood sampled from IDHmt astrocytoma patients was detected with a sensitivity of 56% and a specificity of 97% (n = 206 gliomas and 30 healthy donors). CONCLUSION: The TeloDIAG is a new, simple, and effective tool helping in glioma diagnosis and a promising option for liquid biopsy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Billard P, Guerriau C, Carpentier C, et al. The TeloDIAG: how telomeric parameters can help in glioma rapid diagnosis and liquid biopsy approaches. Ann Oncol. 2021. PMID: 34690007. doi:10.1016/j.annonc.2021.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。